Development
Boston Scientific Corporation
BSX
$102.09
-$0.74-0.72%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 128.08% | 88.06% | 3.17% | 11.36% | -32.95% |
| Total Depreciation and Amortization | 5.28% | 3.98% | 3.66% | 4.37% | 3.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.42% | -58.40% | 19.19% | 90.97% | 701.15% |
| Change in Net Operating Assets | 23.38% | 72.42% | 60.42% | -24.41% | -186.32% |
| Cash from Operations | 64.02% | 96.57% | 78.27% | 16.10% | -18.40% |
| Capital Expenditure | -20.92% | -2.18% | -2.84% | 3.67% | -6.14% |
| Sale of Property, Plant, and Equipment | -66.67% | -57.14% | -62.50% | -61.11% | -14.29% |
| Cash Acquisitions | -17.44% | 43.00% | 63.98% | 85.25% | 31.71% |
| Divestitures | -- | -80.00% | -80.00% | -80.00% | -99.39% |
| Other Investing Activities | -154.90% | -141.00% | -112.26% | -73.08% | -72.80% |
| Cash from Investing | -28.00% | 25.56% | 47.05% | 71.59% | -25.92% |
| Total Debt Issued | -100.00% | -100.00% | -103.42% | -106.41% | -- |
| Total Debt Repaid | 99.88% | 99.88% | 99.97% | 99.97% | -- |
| Issuance of Common Stock | 33.82% | 47.20% | 29.23% | 2.08% | 23.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 49.09% | 25.45% | 0.00% | 0.00% | 0.00% |
| Other Financing Activities | 68.75% | 67.97% | 47.48% | -208.39% | -209.33% |
| Cash from Financing | 100.91% | 98.38% | 36.36% | -10,083.33% | -476.84% |
| Foreign Exchange rate Adjustments | 55.56% | 61.54% | 40.00% | -200.00% | -50.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -200.00% | 200.00% | -100.00% |
| Net Change in Cash | 93.28% | 138.27% | 106.64% | 113.57% | -702.31% |